Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Antrodia camphorata extract** is a botanical drug derived from the medicinal mushroom *Antrodia camphorata*, also known as *Antrodia cinnamomea*. It is a complex natural-product mixture rather than a single defined small molecule, and reported preparations contain ergostane- and lanostane-type triterpenoids, polysaccharides, maleic and succinic acid derivatives, benzoquinone derivatives, lignans, and benzenoid compounds. A specific clinical-stage product is **LEAC-102**, which has undergone a first-in-human Phase I study in healthy volunteers. Preclinical literature attributes pleiotropic anti-inflammatory, hepatoprotective, neuroprotective, and antineoplastic effects to these extracts, with reported modulation of pathways including NF-kappaB and COX-2 and regulation of apoptosis-associated proteins such as the Bcl-2 family. The overall mechanism is therefore best understood as multi-component pathway modulation typical of a botanical extract, with exploratory development in oncology and other disease areas rather than a single validated target-indication pair.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on antrodia camphorata extract.